2019 VCS Annual Conference

Durability of Clinical Response to intratumoral tigilanol tiglate in canine MCT

Campbell, Justine[1]; Johannes Chad[2]; Reddell, Paul[1]
[1]QBiotics, Yungaburra, 4884, QLD, Australia
[2]Iowa State University, Ames, Iowa

Introduction

Tigilanol tiglate is a novel small molecule under evaluation for intratumoral treatment of canine mast cell tumors (MCTs). In clinical studies involving 188 patients, complete response (CR) at 28 days (using RECIST criteria) has averaged 77% (ranging 66% to 90% in individual studies). The objective of this study was to assess the durability of response for up to 12 months after a single treatment with tigilanol tiglate. We also assessed the response from a small number of dogs that received a second injection of tigilanol tiglate following MCT recurrence after the initial treatment.

Methods

Dog with cytologically-confirmed MCT that achieved complete response (CR) in clinical trials with tigilanol tiglate were included in this longitudinal study. Eligible dogs were assessed for recurrence over a 12 month period following initial treatment of their MCT disease. Dogs that developed recurrent tumors during this period received a second injection and their subsequent response was then assessed.

Results

Seventy-four dogs were available for assessment at 12 months following initial CR to tigilanol tiglate. Sixty-five dogs (88%) had no evidence of local MCT recurrence. Nine dogs (12%) developed recurrent tumors at the original treatment site, with four of these recurrences within the first 6 months. Following re-treatment of these 9 dogs, 8 (89%) achieved CR at 28 days.

Conclusion

Intratumoral tigilanol tiglate provided a durable response in dogs treated for MCT, with retreatment of relapsed tumors successful in most cases.